Propanc Biopharma (PPCB) Amortization of Deferred Charges (2014 - 2025)
Propanc Biopharma (PPCB) posted quarterly Amortization of Deferred Charges of $5803.0 for Q4 2025, up 33.96% year-over-year from $4332.0 in Q4 2024, and up 62.23% quarter-over-quarter from $3577.0 in Q3 2025.
Propanc Biopharma (PPCB) Amortization of Deferred Charges (2014 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Amortization of Deferred Charges for 5 consecutive years, with $5803.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Amortization of Deferred Charges rose 33.96% year-over-year to $5803.0; the TTM figure through Dec 2025 stood at $19701.0 (down 3.21% YoY), while the FY2025 annual figure was $20187.0, down 5.49% from the prior year.
- Amortization of Deferred Charges climbed to $5803.0 in Q4 2025 per PPCB's latest filing, from $3577.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $5803.0 in Q4 2025 and bottomed at $3577.0 in Q3 2025.
- Historically, Amortization of Deferred Charges has averaged $5156.6 across 4 years, with a median of $5203.0 in 2023.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 33.96% in 2025 and fell as far as 35.36% in 2025.
- Propanc Biopharma's Amortization of Deferred Charges stood at $5727.0 in 2022, then increased by 0.28% to $5743.0 in 2023, then dropped by 24.57% to $4332.0 in 2024, then soared by 33.96% to $5803.0 in 2025.
- Business Quant data shows PPCB's Amortization of Deferred Charges at $5803.0 in Q4 2025, $3577.0 in Q3 2025, and $5235.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5,803.00 |
| Dec 31, 2025 | 5,803.00 |
| Sep 30, 2025 | 3,577.00 |
| Sep 30, 2025 | 3,577.00 |
| Jun 30, 2025 | 5,235.00 |
| Jun 30, 2025 | 5,235.00 |
| Mar 31, 2025 | 5,086.00 |
| Mar 31, 2025 | 5,086.00 |
| Dec 31, 2024 | 4,332.00 |
| Dec 31, 2024 | 4,332.00 |
| Sep 30, 2024 | 5,534.00 |
| Sep 30, 2024 | 5,534.00 |
| Jun 30, 2024 | 5,764.00 |
| Jun 30, 2024 | 5,764.00 |
| Mar 31, 2024 | 4,724.00 |
| Mar 31, 2024 | 4,724.00 |
| Dec 31, 2023 | 5,743.00 |
| Dec 31, 2023 | 5,743.00 |
| Sep 30, 2023 | 5,128.00 |
| Sep 30, 2023 | 5,128.00 |